OmniAb Secures $370M Deal with Lilly for Ion Channel Program
Event summary
- OmniAb signed a global collaboration and license agreement with Eli Lilly for an undisclosed ion channel program.
- The deal includes an upfront payment plus up to $370M in milestones and tiered royalties on global net sales.
- OmniAb's technology platform will be leveraged for ion channel discovery and screening.
- The therapeutic target and modality remain undisclosed.
The big picture
This collaboration underscores the growing importance of ion channel targets in drug discovery, a space where OmniAb's proprietary transgenic animal platforms offer a competitive edge. The $370M deal potential highlights Lilly's commitment to addressing unmet medical needs through innovative discovery technologies. For OmniAb, this partnership validates its business model and could attract further big-pharma collaborations.
What we're watching
- Program Success
- Whether OmniAb's ion channel discovery platform can deliver breakthrough therapeutics for Lilly.
- Revenue Impact
- The pace at which milestone payments and royalties materialize for OmniAb.
- Pipeline Expansion
- How this deal positions OmniAb for additional high-value partnerships.
Related topics